Kent Bashford, DO
Glaucoma Specialist · Fort Collins, CONPI 1346243714
Payments from drug & device makers
Across 346 payments — averaging $1072.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$257K
- Alcon Research LLC$67K
- Ivantis, Inc$42K
- NEW World Medical,inc.$2K
- Ocular Therapeutix, Inc.$2K
- AbbVie$689
- plus $1K from 16 others
What the payments were for
- Consulting fees$75015%
- Speaking & faculty fees$391%
- Food & beverage$4,22283%
- Education$10%
- Gifts$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 186 | $256,871 |
| Alcon Research LLC | 43 | $66,718 |
| Ivantis, Inc | 14 | $42,310 |
| NEW World Medical,inc. | 25 | $1,506 |
| Ocular Therapeutix, Inc. | 1 | $1,500 |
| AbbVie(2 entities) | 24 | $689 |
| Rxsight Inc | 5 | $519 |
| Alcon | 19 | $327 |
| Akorn, Inc. | 7 | $110 |
| Sight Sciences, Inc. | 2 | $99 |
| Thea Pharma Inc. | 5 | $93 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 2 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $37 |
| Shire North American Group Inc | 2 | $32 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $27 |
| Nova Eye, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $21 |
| Akorn Operating Company LLC | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$750
- Kahook Dual Blade$300
- Clearpath$300
- Ahmed Glaucoma Valve$300
- Streamline$300
- Via360$300
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- XEN$135
- RXSIGHT CONTACT LENS$118
- RXSIGHT INJECTOR CARTRIDGE$118
- RXSIGHT INJECTOR HANDPIECE$118
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$118
- LIGHT ADJUSTABLE LENS (LAL)$118
How this compares
Too few glaucoma specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 189 | $113,451 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $25,296 |
| Alphagan PBrimonidine Tartrate | 40 | $23,901 |
| ProlensaBromfenac Sodium | 60 | $22,035 |
| VyzultaLatanoprostene Bunod | 29 | $19,125 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 77 | $17,180 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $15,132 |
| Travoprost | 66 | $15,079 |
| Latanoprost | 1,040 | $14,035 |
| Brimonidine Tartrate | 206 | $13,323 |
| Prednisolone Acetate | 329 | $10,565 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 509 | $9,236 |
| RhopressaNetarsudil Mesylate | 15 | $8,875 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 35 | $6,966 |
| Travatan ZTravoprost | 13 | $6,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $689 | $162,649285 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $40 | $24,00739 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $37 | $22,03560 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $22 | $19,12529 claims |
| NovartisTravatan Z | $22 | $6,33413 claims |
| AlconSimbrinza | $327 | $4,00113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Fort Collins
- Kyle CottenFort Collins$501
- Malik KahookAurora$2.4M
- Leonard SeiboldAurora$112K
- Stephanie MuylaertLittleton$17K
- Monica ErtelAurora$7K
- Micah RothsteinLongmont$5K
- Jeffrey SoohooAurora$5K
- Anjali ShethLongmont$4K
- Ameay NaravaneLittleton$3K
- Cameron ClarkeDurango$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.